Combination Therapy | malecare.org

Preliminary Data Released for A Phase II Trial of Sipuleucel-T (Provenge) with Concurrent or Sequential Enzalutamide (Xtandi) in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

There will be an abstract presented at the Upcoming (May 31- June 3) American Society of Clinical Oncologist Annual Meeting (ASCO) providing very preliminary data on a clinical trial combing Sipuleucel-T (Provenge) and enzalutamide (Xtandi) in men with metastatic castrate resistant prostate cancer (mCRPC). This rational for conducting this trial is the lack of cross [...]

By Malecare|2020-02-04T10:12:06-05:00May 16th, 2014|Advanced Prostate Cancer, ASCO, Clinical Trials, Clinical Trials, Combination Therapy, Drugs & Treatments, enzalutamide, immunotherapy, Provenge, Uncategorized, vaccines, Xtandi|0 Comments

There is Some Cross Resistance Developed Between Both the First Use of Zytiga and the First Use of Xtandi

On March 4, 2014 I wrote a post “Castrate Resistant Prostate Cancer- What to Do Next” (www.advancedprostatecancer.net/?p=4425). The basic theme of the post was about how difficult it is to know how to sequence the new drugs we have to treat advanced prostate cancer (metastatic castrate resistant prostate cancer aka mCRPC). In the post I [...]

By Malecare|2017-10-19T10:48:32-04:00March 7th, 2014|abiraterone acetate, Advanced Prostate Cancer, Combination Therapy, Cross Resistance, Drugs & Treatments, enzalutamide, Uncategorized, Understanding APC, Xtandi, Zytiga|0 Comments

Long-Term Results Confirm Value of Adding Radio Therapy to ADT for Prostate Cancer Survival

There were many very interesting and very important items presented at the recent ASCO GU conference. Over the course of the next week or two I will be systematically reviewing many of these finds that have a direct impact on men with advanced prostate cancer. Today’s review is about how to create better results for [...]

By Malecare|2020-02-04T10:49:23-05:00February 3rd, 2014|Advanced Prostate Cancer, ASCO, Combination Therapy, Drugs & Treatments, Hormone Therapy, Uncategorized, Understanding APC|0 Comments

A Caution About Yesterday’s Post About Combining Treatments with Chemotherapy

My post to this blog that was written yesterday indicated that for certain men the early use of chemotherapy (docetaxil) could provide significant life extending benefits, especially for men with very advanced prostate cancer. For the purpose of clarification, in this case early use means in men who are still hormone responsive. Given that chemotherapy [...]

By Malecare|2017-10-19T10:49:09-04:00December 7th, 2013|abiraterone acetate, Advanced Prostate Cancer, Chemo Therapy, Clinical Trials, Clinical Trials, Combination Therapy, Drugs & Treatments, ketoconazole, Uncategorized, Understanding APC, Zytiga|1 Comment

Early Chemotherapy for Men Who Are Still Hormone Responsive – For Some It Might Offer Extra Survival

When I was first diagnosed with metastatic prostate cancer one of the first questions that I asked my doctor was whether it made sense for me to start chemotherapy immediately. I very clearly remember him telling me that there was absolutely no evidence that starting chemotherapy at this early stage would do anything to extend [...]

By Malecare|2013-12-06T23:42:14-05:00December 6th, 2013|Advanced Prostate Cancer, Chemo Therapy, Clinical Trials, Clinical Trials, Combination Therapy, Drugs & Treatments, Hormone Therapy, Prostate Ponderings, Uncategorized, Understanding APC, Xtandi, Zytiga|0 Comments